Post Authorisation Safety Study With Raxone in LHON Patients

CompletedOBSERVATIONAL
Enrollment

229

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
Leber's Hereditary Optic Neuropathy (LHON)
Interventions
DRUG

Idebenone

Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.

Trial Locations (26)

8036

Universitaetsklinikum Graz, Graz

11528

Athens Ophthalmological Center, Athens

20132

Ospedale San Raffaele, Milan

20246

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

30029

CHU de Nîmes - Hôpital Carémeau, Nîmes

40123

Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche, Bologna

49033

CHU Angers - Hôpital Hôtel Dieu, Angers

59037

Hopital Roger Salengro - CHU Lille, Lille

69002

Hospices Civils de Lyon, Lyon

69677

Hopital Neurologique Pierre Wertheimer, Lyon

75012

Centre Hospitalier National d'Ophtalmologie (CHNO) des Quinze-Vingts, Paris

75019

Fondation Ophtalmologique Adolphe de Rothschild, Paris

75908

Hôpital Européen Georges Pompidou, Paris

80054

CHU Amiens - Centre Saint Victor, Amiens

97070

Julius Maximilians University, Würzburg

Unknown

Medical University of Vienna, Vienna

Universitaetsklinikum Essen, Essen

Universitaetsklinikum Freiburg, Freiburg im Breisgau

Universitaetsklinikum Heidelberg, Heidelberg

Friedrich-Baur-Institut, Munich

Universitaetsklinikum Muenster, Münster

Dietrich-Bonhoeffer-Klinikum Neubrandenburg, Neubrandenburg

Universitaetsklinikum Regensburg, Regensburg

00152

Azienda Ospedaliera S. Camillo Forlanini, Rome

9713 GZ

Universitair Medisch Centrum Groningen, Groningen

6211 LK

Maastricht University Medical Center, Maastricht

Sponsors
All Listed Sponsors
lead

Santhera Pharmaceuticals

INDUSTRY

NCT02771379 - Post Authorisation Safety Study With Raxone in LHON Patients | Biotech Hunter | Biotech Hunter